M605110

M605110 is an investigational topical pharmaceutical candidate being developed by Maruho Co., Ltd. for the treatment of axillary osmidrosis. Axillary osmidrosis is a condition characterized by an unpleasant odor emanating from the armpits, primarily caused by the bacterial decomposition of apocrine sweat. M605110 is designed for topical application to the axillary region to mitigate this odor. As of 2024, the drug is in Phase II clinical development in Japan (e.g., trial jRCT2031220072), where its efficacy and safety are being evaluated in patients aged 15 years and older. While the specific molecular mechanism of action has not been publicly detailed, treatments for this condition typically involve either reducing sweat production through anticholinergic activity or targeting the odor-producing bacterial flora on the skin surface.